clinical trial · NCT07652047
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Obesity & OverweightCX11PlaceboCX11
brief summary
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
started
May 11, 2026
primary completion
Mar 1, 2027
completion
Jun 1, 2027
last updated
Jun 16, 2026
official title
A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol